Download Image
    
Share
  
Post
Emvododstat for COVID-19
1 study with 187 patients
Hospital Icon Control
Hospital Icon Emvododstat Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Emvododstat studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -132% Mortality -132% RCTs -132% Late -132% Favorsemvododstat Favorscontrol
Jun 26
2023
 Ngumah et al., NCT04439071 Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)
132% higher mortality (p=0.16) and 47% higher ventilation (p=0.31). RCT 189 hospitalized patients showing higher mortality with emvododstat (PTC299), without statistical significance.
Jan 31
2021
 Luban et al., Virus Research, doi:10.1016/j.virusres.2020.198246 The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines
In vitro study showing that PTC299, a dihydroorotate dehydrogenase inhibitor, inhibited SARS-CoV-2 replication with an EC50 of 1.96-31.6 nM and reduced inflammatory cytokine production. PTC299 had broad antiviral activity against HCV, pol..